Selective N‐Terminal BET Bromodomain Inhibitors by Targeting Non‐Conserved Residues and Structured Water Displacement. (18th November 2020)

• Record Type: Journal Article
• Authors: Cui, Huarui; Divakaran, Anand; Pandey, Anil K.; Johnson, Jorden A.; Zahid, Huda; Hoell, Zachariah J.; Ellingson, Mikael O.; Shi, Ke; Aihara, Hideki; Harki, Daniel A.; Pomerantz, William C. K.
• Is Part Of: Angewandte Chemie. Volume 133:Number 3(2021)
• Page Start: 1240
• Page End: 1246
• Publication Date: 2020-11-18
• Subjects: BET bromodomains -- BRD4 D1 selectivity -- epigenetics -- inhibitors -- structure-activity relationships; Chemistry -- Periodicals; 540
• DOI: 10.1002/ange.202008625
• Languages: English
• ISSNs: 0044-8249

Abstract

Abstract: Bromodomain and extra‐terminal (BET) family proteins, BRD2‐4 and T, are important drug targets; however, the biological functions of each bromodomain remain ill‐defined. Chemical probes that selectively inhibit a single BET bromodomain are lacking, although pan inhibitors of the first (D1), and second (D2), bromodomain are known. Here, we develop selective BET D1 inhibitors with preferred binding to BRD4 D1. In competitive inhibition assays, we show that our lead compound is 9–33 fold selective for BRD4 D1 over the other BET bromodomains. X‐ray crystallography supports a role for the selectivity based on reorganization of a non‐conserved lysine and displacement of an additional structured water in the BRD4 D1 binding site relative to our prior lead. Whereas pan‐D1 inhibitors displace BRD4 from MYC enhancers, BRD4 D1 inhibition in MM.1S cells is insufficient for stopping Myc expression and may lead to its upregulation. Future analysis of BRD4 D1 gene regulation may shed light on differential BET bromodomain functions. Abstract : The twin‐bromodomain‐containing BET proteins, BRD2‐4 and T, are important drug targets for inflammation, cancer, and heart disease. However, potent and selective inhibitors for a single BET bromodomain are lacking. Here we describe the structure‐based design of inhibitors with preferred binding for the first bromodomain of BRD4, and provide design rules for future inhibitors. Cell‐based studies identify differential effects relative to pan‐BET inhibitors.